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Abstract
Background: Previous studies have shown that liver function is inhomogeneously distributed in dis-
eased livers, and this uneven distribution cannot be compensated for if a global liver function test is used
for the prediction of post-operative remnant liver function. Dynamic Gd-EOB-DTPA-enhanced magnetic
resonance imaging (MRI) can assess segmental liver function, thus offering the possibility to overcome
this problem.
Methods: In 10 patients with liver cirrhosis and 10 normal volunteers, the contribution of individual liver
segments to total liver function and volume was calculated using dynamic Gd-EOB-DTPA-enhanced MRI.
Remnant liver function predictions using a segmental method and global assessment were compared for
a simulated left hemihepatectomy. For the prediction based on segmental functional MRI assessment, the
estimated function of the remnant liver segments was added.
Results: Global liver function assessment overestimated the remnant liver function in 9 out of 10 patients
by as much as 9.3% [median −3.5% (−9.3–3.5%)]. In the normal volunteers there was a slight underes-
timation of remnant function in 9 out of 10 cases [median 1.07% (−0.7–2.5%)].
Discussion: The present study underlines the necessity of a segmental liver function test able to
compensate for the non-homogeneous nature of liver function, if the prediction of post-operative remnant
liver function is to be improved.
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Introduction
In spite of improvement in the outcome of liver surgery during
the last decades, post-operative liver failure remains a feared com-
plication and is currently the leading cause of post-operative
mortality.1–3 In patients with normal liver function, a future liver
remnant (FLR) of 25% is usually sufficient for maintenance of
immediate post-operative function and regeneration.4,5 In these
patients, decision making regarding the FLR is purely volume-
based, using computed tomography (CT) or magnetic resonance
imaging (MRI) volumetry. In patients with underlying parenchy-
mal disease, for example cirrhosis, the impaired liver function has
to be considered in the decision making by increasing the size of
the FLR in relation to the degree of dysfunction. Various methods
to assess liver functional reserve and predict the remnant function
have been proposed and are used.6 These include biochemical
serum liver function tests, composite scoring models such as the
Child–Pugh and model for end-stage liver disease scores, but also
more complex methods for dynamic assessment of liver enzyme
systems such as the LiMAx® test and indocyanine green (ICG)
clearance are used, yielding a quantitative assessment of global
liver function.6,7 In a survey of hepato-pancreato-biliary and
transplant centres, large variations in what is regarded as critical
liver mass for liver resection were found.8 For healthy livers the
critical size was 25% (range 15–40%) and for patients with cir-
rhosis 50% (range 25–90%). What is particularly striking is the
large range in what respondents regard as the critical size in
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patients with cirrhosis. This could be as a result of the wide spec-
trum in disease severity in the cirrhosis population, but could also
reflect a lack of confidence in and precision of the existing
methods to evaluate liver function. The survey also showed large
differences in the use of pre-operative metabolic tests to assess
liver function.9
A prerequisite for a global liver function test or pure volumetry-
based assessment to be accurate in predicting post-operative
remnant liver function is that the functional capacity and disease
distribution is homogeneous within the liver. Several previous
studies have shown that this is not the case in liver cirrhosis.10–14 A
way to overcome this problem is to use an imaging-based method
that enables sampling from different parts of the liver for func-
tional assessment in a non-invasive fashion. This principle has
been applied in scintigraphic methods, either using 99MTc-GSA
scintigraphy or iminodiacetic acid (IDA) compounds.15
Gadoxetic acid or Gd-EOB-DTPA (Primovist®/Eovist®; Bayer
Healthcare AG, Berlin, Germany) is a gadolinium-based contrast
agent for T1-weigthed MRI, used to improve the detection and
characterization of liver lesions.16,17 Gadoxetic acid is hepatocyte
specific in the sense that it is taken up into hepatocytes by the
OATP 1B1/B3 transporter system, and excreted into bile by the
ATP-dependent MRP2-complex, these transport pathways being
similar to those for the uptake and excretion of ICG and the IDA
substances.18–21 Gd-EOB-DTPA has therefore been proposed as a
suitable substance for imaging-based liver function assessment
using MRI as the imaging modality. Several studies have con-
firmed a correlation between liver function and various imaging
parameters obtained from Gd-EOB-DTPA-enhanced MRI.22–26 In
an attempt to quantitatively assess the uptake of Gd-EOB-DTPA,
deconvolutional analysis has been proposed and the method pre-
viously extensively described.27 Using this algorithm, the hepatic
extraction fraction (HEF), as a measurement of parenchymal
function, and the input relative blood flow (irBF), as a measure-
ment of perfusion, can be calculated. These parameters have been
studied in patients with primary biliary cirrhosis, primary sclero-
sing cholangitis and liver cirrhosis13,28,29
The aim of this study was to demonstrate, with the use of
Gd-EOB-DTPA-enhanced MRI, how non-homogeneous distri-
bution of liver function might impact the prediction of remnant
liver function if a global liver function test is used, as opposed to
a segment-based functional analysis.
Patients and methods
Study subjects
Ten patients with varying degrees of alcohol- and/or viral
hepatitis-induced liver cirrhosis were included. The control group
consisted of the 10 normal volunteers. Informed consent was
obtained from all participants prior to inclusion, and the study
was approved by the Regional Ethical Review Board in Stockholm.
Demographic and clinical parameters of the study subjects,
including Child–Pugh scores calculated for each patient, are sum-
marized in Table 1.
Table 1 Study subject characteristics
Patients (n = 10) Controls (n = 10) P-value Reference
Gender (m/f) 8/2 5/5 P = 0.18a
Age (median, min-max) 57 (43–61) 32 (22–38) P < 0.05b
Mean (SD) Mean (SD)
Bilirubin (μmol/l) 35 (22.6) 16 (5.9) P < 0.05b (<26)
Albumin (g/l) 32 (7.7) 42 (2.5) P < 0.05b (36–48)
Creatinine (μmol/l) 91 (22.8) 80 (15.3) P = 0.22 [<100 (men); <90 (women)]
PK-INR (INR) 1.4 (0.29) 1.1 (0.07) P < 0.05b (<1.2)
ALP (μkat/L) 2.3 (1.04) 1.2 (0.61) P < 0.05b (<1.9)
ALT (μkat/L) 0.97 (0.69) 0.51 (0.31) P = 0.08 [<1.20 (men); <0.76 (women)]
AST (μkat/L) 1.47 (1.1) 0.34 (0.09) P < 0.05b [<0.76 (men); <0.61 (women)]
Disease characteristics of patients
Median (min–max)
CPS 7 (5–12)
Child–Pugh class (n)
A 4
B 5
C 1
aFisher's exact test.
bMann–Whitney U-test.
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CPS, Child–Pugh score; PK–INR, prothrombin complex–
International normalized ratio.
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MRI procedure
All subjects were instructed to fast for at least 4 h prior to the
examination. MR imaging was performed using a Philips Intera
1.5 Tesla (T) scanner (Best, The Netherlands), with a Philips four-
channel SENSE body coil. The dynamic contrast-enhanced
sequence was performed using a T1-weighted 3-D spoiled-
gradient-echo sequence [repetition time/echo time/flip angle
4.1 ms/2.0 ms/10°, field of view (FOV) = 415 mm, acquisition
matrix resolution 192 × 192, reconstruction matrix 256 × 256, 40
slices, slice thickness 10 mm with 5 mm overlap and SENSE factor
R = 2]. These imaging parameters yielded a volume element
(voxel) volume of approximately 13 mm3 (1.62 × 1.62 × 5 mm). A
voxel is the three-dimensional equivalent of a pixel (a picture
element), being the smallest unit in a raster image. The volume
was examined in a single breath-hold at 35 different time points
(12 s scan time per acquired volume) and the subjects were asked
to hold their breath at the same depth during each acquisition.
Three volumes were acquired pre-contrast for calculations of
baseline signal intensity, followed by repetitive sampling with a
step-wise increase in sampling intervals up to a total sampling
time of 45 min. The control group had been examined with a
study protocol implying a total sampling time of 90 min, but in
this study only acquisitions up to 45 min post contrast injection
were used, meaning that the sampling time points and imaging
parameters were identical in the two groups. A dose of 0.1 ml/kg
Gd-EOB-DTPA 0.25 mmol/ml was injected into the anterior
cubital vein, coinciding with the start of the fourth acquired
volume. The contrast was injected using a power injector (Spectris
MR injector System; Medrad, Pittsburgh, PA, USA), at an infusion
rate of 2 ml/s, followed immediately by a bolus of 20 ml of saline
(NaCl 0.9%) at the same infusion rate.
Liver segmentation and image analysis
From a seed-point placed in the inferior vena cava, lines were
drawn in the plane of the right hepatic vein, middle hepatic vein
and the falciform ligament/umbilical fissure creating the vertical
inter-sectorial and inter-segmental boundaries. Segment I was
manually outlined in every slice where it was visible according to
the anatomical landmarks as described by Dodds et al.30 The hori-
zontal inter-segmental plane was defined as being in the image
slice where the division of the portal vein into the left and right
portal branches was identified. Fifty per cent of the voxels in this
slice was regarded as representative of segments 2, 4a, 7 and 8, and
50% as part of segments 3, 4b, 5 and 6. The liver contour was
manually outlined in every slice, with the major hilar structures
being excluded. The volumes of the voxels within the liver
boundaries were added to obtain total and segmental liver
volumes for each subject. Image analysis and subsequent calcula-
tions were performed using in-house software written in
MATLAB® (Mathworks, Novi, MI, USA).
Liver function parameters
HEF and irBF were calculated for every voxel within the liver
using Fourier transforms as described in a previous study.27
The input function was defined by a region of interest (ROI)
placed in the spleen. To ensure that the ROI in the spleen was truly
representative of the blood content over the entire acquisition
period, it was manually adjusted when needed. A HEF above 0.7
or irBF above 1 was regarded as artefact and omitted from subse-
quent analysis. Voxels representing vascular structures were
expected to have high perfusion and therefore high irBF values,
and therefore voxels with an irBF above a user-defined threshold
were regarded as representing vessels and not parenchyma and
consequently omitted from analysis of parenchymal function and
volume. Total liver volumes including vessel volume, as well as
parenchymal volumes excluding vessels, were calculated. Total
liver parenchymal function and parenchymal volume were
obtained by adding the individual HEF and volume of all paren-
chymal voxels within the liver boundaries and expressed as
HEFml. For every segment, the volume and functional capacity
were calculated in the same way by adding the volume and func-
tion of all parenchymal voxels within the predefined segmental
borders. The global median HEF was obtained by calculating
the median HEF of all parenchymal voxels within the liver
boundaries.
Hepatectomy simulation
A left hemi-hepatectomy implying the removal of segments 2, 3
and 4 was simulated and residual post-operative function as pre-
dicted by global assessment versus segmental assessment was
compared. The residual function as predicted by an arbitrarily
chosen global liver function test was calculated by deducting the
percentage of the total hepatocyte extraction capacity (HEFml)
equivalent to the percentage of the volume of liver parenchyma
resected. For the simulation of the prediction based on segmental
functional assessment, the estimated function (in HEFml) of the
remaining liver segments was added. For example, if resection
implied removal of 45% of the liver volume, the predicted
remnant liver function using global assessment was calculated as
being 55% of the total liver function, whereas the measured func-
tion in HEFml of segments 1, 5, 6, 7, and 8 was added for the
segmental function-based prediction.
Statistical analysis
Descriptive statistics were used to present clinical characteristics
of the study subjects and the quantitative liver function param-
eters. Non-parametric tests (Mann–Whitney U-test and Fisher’s
exact test) were used for group comparisons. The significance
threshold was set to α = 0.05. STATA 10 (StataCorp, College
Station, TX, USA) was used for the statistical analyses.
Results
The results of liver volume measurements and of the quantitative
functional parameters in both groups are shown in Table 2. There
were no significant differences regarding total liver volume,
but when vascular voxels were not included, the patient group
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had significantly larger parenchymal volume. In spite of the
larger liver volume in the patient group, the overall parenchymal
function expressed as HEFml was significantly lower, as was the
median HEF, indicating a decreased parenchymal functional
capacity.
The results of the simulated hemi-hepatectomy are presented in
Fig. 1 and Table 3. In the normal volunteers there was a slight
underestimation of residual function in 9 out of 10 patients
[median 1.07% (range −0.7–2.5%)]. Global liver function assess-
ment overestimated the remnant liver function in 9 out of 10
patients by as much as 9.3% in absolute numbers [median −3.5%
(range −9.3–3.5%)], and the difference between the groups was
statistically significant. If the actual value of the residual function
as estimated by the segmental method is used as a reference, the
miscalculation or error using the global assessment was as much
as 26% (9.3% out of 35.2%), as shown in Table 3. There seemed to
be a more pronounced function-to-volume discrepancy in the
Child–Pugh B & C patients compared with those with Child–
Pugh A, as presented in Fig. 2. Formal statistical testing was not
carried out owing to the low number of subjects in each group.
Discussion
In patients with diseased liver considered for liver resection,
volume-based decision making alone is not sufficient. The degree
of dysfunction has to be accounted for in the decision-making
algorithm. All methods currently used in clinical practice for func-
tional analysis give a global assessment of liver function, and
these tests are not able to detect and correct for eventual
inhomogeneous distribution of liver function.
Certainly, not all the patients included in this study could be
candidates for a liver resection, should an indication arise,
but the hepatectomy simulation does however demonstrate
that relying on a global test in patients with significant
inhomogeneity may result in over- or under-estimation of liver
function. A difference between the left and right livers regarding
the volume/function discrepancy was observed. There seems to
be an overestimation of function in a right hemiliver, as opposed
to an underestimation of function in a left hemiliver. Both the
scenarios have consequences for the patient as overestimating
liver function might result in liver failure, whereas underestima-
tion might preclude patients from potential curative treatment
by overestimating the risk for post-operative failure. Even if
global tests are likely to be become more comprehensive, maybe
even giving information on multiple metabolic pathways, the
results in this study argue strongly in favour of incorporating
data on segmental liver function in the pre-operative assessment
of liver functional reserve.
Liver disease in patients considered for a liver resection has
previously almost exclusively been limited to cirrhosis in patients
with hepatocellular carcinoma, but with the increasing use of
neo-adjuvant chemotherapy for colorectal cancer liver metastases,
patients presenting with sinusoidal obstruction syndrome and
chemotherapy-associated steatohepatitis are frequently encoun-
tered in the setting of liver surgery.3,31,32 As obesity is becoming
more and more prevalent, the metabolic syndrome-associated
conditions of non-alcoholic fatty liver disease and non-alcoholic
steatohepatitis, which may in turn lead to liver cirrhosis, have
become the most common chronic liver diseases in the western
world.33,34 Both chemotherapy-induced liver injury and obesity-
associated hepatic disease have been shown to be non-
homogeneously distributed in the liver.13,28,35–38
Table 2 Results of liver function and volume analysis
Controls Patients P-valuea
Median (min–max) Median (min–max)
Total liver volume (ml) 1463.0 (1076–1724) 1577.0 (1357–1886) P = 0.13
Parenchymal volume (ml) 1250.0 (957–1642) 1435.0 (1225–1774) P < 0.05
Total functional capacity (HEFml) 267.0 (215–383) 171.0 (53–341) P < 0.05
Standardized functional capacitcy (HEFml/m2)b 141.0 (128–222) 84.0 (32–172) P < 0.05
Global median HEF 0.22 (0.19–0.28) 0.10 (0.02–0.20) P < 0.05
aMann–Whitney U-test.
bTotal functional capacity in HEFml/body surface area.
Figure 1 The difference in predicted function versus actual function
based on a segmental assessment in the patient and the control
group. The difference was significantly larger in the patient group
with two patients showing an almost 10% difference
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In conclusion, this study demonstrates the non-homogeneous
distribution of liver function in cirrhotic patients, and probably
not only in this group, regional function assessment has to be
added to the equation in order to minimize the risk of post-
operative liver failure and possibly death. Patients considered for a
liver resection should not be subjected to unnecessary risks by
overestimating liver function in the residual liver. Nor should
patients that are in fact eligible for surgery be excluded from
potential curative treatment owing to underestimation of residual
function.
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